Company intelligence / Profile preview

Anthos Therapeutics

Cambridge, Massachusetts, United Statesanthostherapeutics.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Phase 2 data (AZALEA-TIMI 71) showed abelacimab led to significant reduction in bleeding events compared to standard of care direct-oral anticoagulant in patients with atrial fibrillation. Currently conducting three Phase 3 trials: LILAC-TIMI 76 for atrial fibrillation, and ASTER and MAGNOLIA for cancer-associated thrombosis. Data expected in second half of 2026.[3][6][7]

Therapeutic areas: HematologyCardiovascular
Modalities: Monoclonal antibodies
Industry: Biotech

Drug pipeline

1 asset

abelacimab

Phase 3

Indications: Atrial fibrillation, Cancer-associated thrombosis, Venous thromboembolism, Stroke prevention

Partnerships

Novartis

Beyond the preview

Go deeper on Anthos Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anthos Therapeutics.

Explore the full profile